EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism

Ariel Haber, Ada Selina Jutba, Haya Kaseer, Moustafa Younis, Ali Ataya

American Journal of Critical Care · 01.11.2026 · 35 (6) · 475-480

DOI: 10.4037/ajcc2026126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Critical Care, online erschienen am 01.11.2026. Verfasst von Ariel Haber und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ariel Haber is a pharmacist, Department of Pharmacy, University of Florida Health, Gainesville, Florida. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Pulmonary Embolism, Fibrinolytic Agents. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal dosing of alteplase in patients with high-risk pulmonary embolism is widely debated.

Objective

To evaluate outcomes in patients with high-risk pulmonary embolism who received alteplase at a low dose or a standard dose.

Methods

This was a retrospective cohort analysis of 65 patients who received alteplase for high-risk pulmonary embolism at a large academic medical center between June 1, 2011, and August 31, 2022. Patients were placed in 2 cohorts according to initial dose: low-dose alteplase (50 mg) and standard-dose alteplase (100 mg). The primary outcome was sustained hemodynamic stability within 24 hours of the start of alteplase infusion. Secondary outcomes included in-hospital mortality, duration of mechanical ventilation, hospital and intensive care unit length of stay, and major bleeding.

Results

The primary outcome of sustained hemodynamic stability within 24 hours did not differ significantly between the 2 cohorts (achieved in 32% of patients in the low-dose group and 38% in the standard-dose group; P = .65). In-hospital mortality did not differ significantly between groups (48% in the low-dose group vs 45% in the standard-dose group; P = .81). Patients in the low-dose group had fewer days of mechanical ventilation than patients in the standard-dose group (1.5 vs 6 days; P = .03) and a smaller percentage had major bleeding (12% vs 25%; P = .34).

Conclusions

In patients with high-risk pulmonary embolism, sustained hemodynamic stability within 24 hours did not differ significantly between low-dose and standard-dose alteplase treatment strategies. Low-dose alteplase may be an appropriate alternative dosing strategy for patients with high-risk pulmonary embolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Plasminogen ActivatorPulmonary EmbolismFibrinolytic AgentsHumansRetrospective StudiesFemaleMaleHospital MortalityMiddle AgedAgedDose-Response Relationship, DrugTreatment OutcomeRespiration, ArtificialLength of StayIntensive Care UnitsHemorrhage

Substanzen

Tissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Ariel Haber is a pharmacist, Department of Pharmacy, University of Florida Health, Gainesville, Florida.
  • Ada Selina Jutba is a pharmacist, Department of Pharmacy, Memorial Hermann-Memorial City Medical Center, Houston, Texas.
  • Haya Kaseer is a pharmacist, Department of Pharmacy, University of Florida Health, Gainesville, Florida.
  • Moustafa Younis is a lung transplant physician, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida Health, Gainesville.
  • Ali Ataya is a critical care physician, Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida Health, Gainesville.

Zitieren

APA

Haber, A., Jutba, A. S., Kaseer, H., Younis, M., & Ataya, A. (2026). Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism. American Journal of Critical Care, 35(6), 475-480. https://doi.org/10.4037/ajcc2026126

Vancouver

Haber A, Jutba AS, Kaseer H, Younis M, Ataya A. Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism. American Journal of Critical Care. 2026;35(6):475-480. doi:10.4037/ajcc2026126

BibTeX
@article{Haber2026,
  author = {Haber, Ariel and Jutba, Ada Selina and Kaseer, Haya and Younis, Moustafa and Ataya, Ali},
  title = {Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism},
  journal = {American Journal of Critical Care},
  year = {2026},
  volume = {35},
  number = {6},
  pages = {475--480},
  doi = {10.4037/ajcc2026126}
}
Kostenlos starten →